Cancer (stem) cell differentiation: An inherent or acquired property?
There is a growing list of data indicating that cancer (stem) cells could functionally adapt foreign tissue features, such as endothelial-like cells or neuroendocrine cells, express lineage markers or could differentiate into various lineages in response to appropriate differentiation criteria. The finding that cancer (stem) cells may possess some kind of differentiation capacity poses the question whether this might be an inherent or acquired property. Cancer stem cells share stem cell characteristics and may thus possess an inherent differentiation capacity enabling the cells to respond to various differentiation stimuli. Considering the plasticity of cancer (stem) cells, even non-tumorigenic (and putatively non-differentiable) tumor cells could give rise to tumorigenic tumor stem cells, exhibiting stem cell characteristics including an inherent differentiation capacity. On the contrary, cancer (stem) cells may have acquired differentiation capacity as a consequence of a previous cell fusion event with cell types exhibiting differentiation potential and being fusogenic, such as macrophages or stem cells. Of pivotal interest in a tumor context are macrophages, which chiefly foster the chronically inflamed tumor microenvironment. Because chronically inflamed tissue is a well-known trigger for cell fusion and both macrophages and stem cells are highly fusogenic we conclude that cell fusion events between these cell types and cancer (stem) cells should frequently occur, thereby giving rise to hybrid cells exhibiting not only novel properties, like an enhanced metastatogenic phenotype, but also parental characteristics, such as differentiation capacity. Conceivably, the combination of both properties might be advantageous for metastasizing cancer (stem) cells to adapt better and faster to a foreign organ tissue environment.
Institute of Immunology & Experimental Oncology, Research Group Stem Cells, Center for Biomedical Education and Research, Witten/Herdecke University, Stockumer Str. 10, 58448 Witten, Germany.
Marieke
M
Mohr
Institute of Immunology & Experimental Oncology, Research Group Stem Cells, Center for Biomedical Education and Research, Witten/Herdecke University, Stockumer Str. 10, 58448 Witten, Germany.
Kurt S
KS
Zänker
Institute of Immunology & Experimental Oncology, Research Group Stem Cells, Center for Biomedical Education and Research, Witten/Herdecke University, Stockumer Str. 10, 58448 Witten, Germany. Electronic address: thomas.dittmar@uni-wh.de.
Thomas
T
Dittmar
D000818:Animals; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D019070:Cell Lineage; D042783:Endothelial Cells / Q000473:pathology; D005260:Female; D005819:Genetic Markers / Q000235:genetics; D007249:Inflammation; D008264:Macrophages / Q000378:metabolism; D015674:Mammary Neoplasms, Animal / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism; D051379:Mice; D009362:Neoplasm Metastasis; D014411:Neoplastic Stem Cells / Q000166:cytology*; D015675:Osteocalcin / Q000378:metabolism; D010641:Phenotype; D059016:Tumor Microenvironment; D014945:Wound Healing
D005819:Genetic Markers; D015675:Osteocalcin